Introduction
============

Emergence agitation (EA) is a common phenomenon during recovery from general anesthesia. Behavioral changes in patients, including restlessness, disorientation, and excitation, may easily cause involuntary physical accidental injury. Moreover, restlessness can induce sympathetic excitement, which probably raises blood pressure and heart rate (HR) and increases myocardial oxygen consumption and the risk of cardiovascular and cerebrovascular diseases.[@b1-tcrm-12-713] An effective prevention of EA plays an important role in clinical anesthesia outcomes and evaluation.[@b2-tcrm-12-713]

EA in patients recovering from general anesthesia is attributed to complicated causes, and one of the most confounding factors is the postoperative pain caused by reduction of anesthesia effect.[@b3-tcrm-12-713] Ultrashort-acting drugs such as remifentanil have been used for sedation, and have also been combined with other medications for use in general anesthesia.[@b4-tcrm-12-713] Due to the relatively short context-sensitive half-life of remifentanil, the desired blood plasma level can be achieved quickly and recovery occurs faster; postoperative pain in the recovery phase is unbearable, which contributes to the incidence of EA.[@b5-tcrm-12-713] Therefore, it is necessary to take appropriate measures for prevention of EA. Intravenous morphine, fentanyl, and other opioids were used previously to reduce incidence of EA, but those drugs could not effectively ease the postoperative pain, as well as nausea, vomiting, delayed recovery, respiratory depression, and chest wall muscle rigidity.[@b6-tcrm-12-713] Investigating safer and more efficient measures for prevention of EA has become the major challenge faced by clinical anesthesiologists.

Ketamine and butorphanol are effective drugs for analgesia routinely used in the clinical practice. Although preoperative injection of ketamine or butorphanol can reduce the incidence of EA, the combined application of ketamine and butorphanol in practice is not reported yet.[@b7-tcrm-12-713]--[@b9-tcrm-12-713] This study aimed to investigate the preventive effect of different drugs (butorphanol, ketamine, and combination of butorphanol and ketamine) on EA in patients with gastric cancer.

Materials and methods
=====================

Subjects
--------

This study was carried out among 150 patients with gastric cancer who underwent radical surgery from the First Affiliated Hospital of Xiamen University, People's Republic of China, between October 2014 and October 2015. All patients met the following criteria. Inclusion criteria were the diagnosis of gastric cancer by gastroscopy or pathological examination, submission of signed informed consent form, and the absence of any surgical contraindication. Exclusion criteria were patients with psychosis, anaphylactic reactions to drugs, severe cardiovascular and cerebrovascular disease, and opiod addiction. Approximately 150 patients were divided into three groups, and no differences were found in characteristics between the groups, as shown in [Table 1](#t1-tcrm-12-713){ref-type="table"}. This study was approved by the ethics committee of the Affiliated Hospital of Xiamen University. All patients provided written informed consent.

Anesthesia methods
------------------

Patients were assigned to receive intravenous midazolam (0.05--0.10 mg/kg), propofol (1.5--2.0 mg/kg), vecuronium (0.1 mg/kg), and fentanyl (2 μg/kg) as the anesthetic induction agent. General anesthesia was maintained with propofol (4.0--6.0 mg/kg), vecuronium (0.1--0.2 mg/kg), and remifentanil (0.1--0.2 μg/kg). Patients in group B were injected with 1 mg butorphanol as premedication, those in group K were injected with 1 mg/kg ketamine, and the rest of the patients (group C) were injected with 1 mg butorphanol combined with 1 mg/kg ketamine. All individuals were transferred to the postanesthesia care unit (PACU) after operation.

Examination
-----------

The following characteristics were measured: Vital sign: the mean arterial pressure (MAP) and HR at the end of operation just before extubation (T0), and at 0 minute (T1), 5 minutes (T2), and 30 minutes (T3) after extubation;anesthesia recovery: the recovery time, extubation time, and time in the PACU;the stage of EA: stage 0: quiet; stage 1: slightly restless to stimuli; stage 2: obviously excited without stimulation; stage 3: delirious and struggling and shouting continuously. for the formula for calculation of incidence of EA is: $$\text{Incidence} = \frac{\begin{matrix}
{\text{Number}\ \text{of}\ \text{cases}} \\
\left( {\text{stage}\ 1 + \text{stage}\ 2 + \text{stage}\ 3} \right) \\
\end{matrix}}{\text{Total}\ \text{number}\ \text{of}\ \text{cases}} \times 100\%$$adverse reactions: drowsiness, glossoptosis, respiratory depression, etc.

Statistical analysis
--------------------

Statistical analyses were performed using the SPSS statistical package, version 18.0 (SPSS Inc., Chicago, IL, USA). The measurement data were analyzed by analysis of variance and expressed as mean ± standard deviation, the enumeration data were expressed as number of cases. The incidence was determined by *χ*^2^ test, with a significance of *P*\<0.05.

Results
=======

Vital sign
----------

In this study, no significant differences were found in multiple comparison among groups with respect to MAP and HR at T0 and T1 (*P*\>0.05). Compared with patients in group C, significant reduction of MAP and HR were observed in groups K and B at T2 and T3 (*P*\<0.05), while no difference were found between group K and group B (*P*\>0.05, [Table 2](#t2-tcrm-12-713){ref-type="table"}). The results showed that injection of ketamine combined with butorphanol before anesthesia induction was more effective than injection of ketamine or butorphanol separately with regard to the vital sign stability.

Anesthesia recovery
-------------------

As shown in [Table 3](#t3-tcrm-12-713){ref-type="table"}, we found that the recovery time, extubation time, and time in the PACU in group C were significantly less than those in groups K and B (*P*\<0.05). However, no differences were observed between group K and group B (*P*\>0.05). The data suggested that injection of concomitant drugs (ketamine and butorphanol) before anesthesia might contribute to improve the quality of anesthesia recovery than injection of each drug separately.

Incidence of EA
---------------

In this study, we found the incidences of EA in group C, group K, and group B were 6.0% (3/50), 24.0% (12/50), and 20.0% (10/50), respectively. The incidence of EA in group C was remarkably lower than those in groups K and B (*χ*^2^=6.353, 4.332; *P*\<0.05), but the difference between group K and group B did not reach statistical significance ([Table 4](#t4-tcrm-12-713){ref-type="table"}, *χ*^2^=0.233, *P*\>0.05). The results indicated that combined application of ketamine and butorphanol could greatly abate the incidence of EA.

Incidence of adverse reactions
------------------------------

In our data, the incidence of adverse reactions were greatly increased in group K compared with those in groups C and B ([Table 5](#t5-tcrm-12-713){ref-type="table"}, *χ*^2^=5.316, *P*\<0.05), while no statistical significance was found between group C and group B ([Table 5](#t5-tcrm-12-713){ref-type="table"}, *χ*^2^=0.000, *P*\>0.05). It was suggested that using ketamine combined with butorphanol might be beneficial in reducing the incidence of adverse reactions than using each drug separately.

Discussion
==========

Butorphanol is a morphinan-type synthetic opioid analgesic that exhibits partial agonist and antagonist activity at the μ-opioid receptor, as well as competitive antagonist activity and partial agonist activity at the κ-opioid receptor. The analgesic potency of butorphanol was five to eight times that of morphine, while the respiratory depression was only one-fifth as much as that of the latter.[@b10-tcrm-12-713]--[@b14-tcrm-12-713] A previous study reported that butorphanol could reduce the incidence of EA in patients recovering from general anesthesia, but prolong the recovery time of emergence.[@b15-tcrm-12-713]

Ketamine is classified as an *N*-methyl-D-aspartic ammonia acid receptor antagonist, and it is a medication used mainly for starting and maintaining anesthesia. Ketamine is an analgesic that is most effective when used alongside a low-dose opioid; while it does have analgesic effects by itself, the doses required for adequate pain relief when it is used as the sole analgesic agent are considerably higher and far more likely to produce disorienting side effects.[@b16-tcrm-12-713]--[@b19-tcrm-12-713] In our study, we found that the incidence of adverse reactions were greatly increased in those injected with 1 mg/kg ketamine before anesthesia induction than those injected with butorphanol (*P*\<0.05). In addition, injection with ketamine combined with butorphanol before anesthesia could efficiently shorten recovery time and reduce incidence of adverse reactions than application of each drug separately. The results indicated that use of concomitant drugs would not cause oversedation and could be used safely. As previously reported, the incidence of EA in patients with gastric cancer was \~30%.[@b14-tcrm-12-713] According to our study, combined application of ketamine and butorphanol could remarkably reduce the incidence of EA to 6% (3/5). This suggested that ketamine combined with butorphanol might have a synergistic action on the analgesic effect because of different pain reflex arc.[@b20-tcrm-12-713]

Based on the findings reported from our study, we speculate that there are may be more promise for the use of ketamine and butorphanol in the other clinically significant areas. In the clinic, both ketamine and butorphanol have been proven to be the effective drugs for analgesia.[@b7-tcrm-12-713]--[@b9-tcrm-12-713] Mahran and Hassan[@b21-tcrm-12-713] reported that ketamine is effective in postoperative pain management in breast cancer surgery. Minoshima et al[@b22-tcrm-12-713] also proved that ketamine could play an important role post-operation following adolescent idiopathic scoliosis surgery. Moreover, butorphanol was also applied in therapy of some diseases or for surgery.[@b23-tcrm-12-713] Stambaugh and McAdams[@b24-tcrm-12-713] found that butorphanol could act as an effective drug in chronic cancer pain. Kaur and Bajwa[@b25-tcrm-12-713] reported that the butorphanol could also be used in lower abdominal surgery.

In this study, we found the incidences of EA in group C, group K, and group B were 6.0%, 24.0%, and 20.0% (10/50), respectively. These results suggested that the butorphanol combined with ketamine could decrease the rate of complication compared to butorphanol and ketamine used separately. Previous studies[@b26-tcrm-12-713]--[@b28-tcrm-12-713] have proved that both ketamine and butorphanol could improve or decrease the EA in the clinic. However, the EA occurrence (side effect) triggered by ketamine or butorphanol is also not acceptable. In this study, we combined ketamine and butorphanol together and discovered that they cooperated with each other to decrease the EA. The specific mechanism for the effects of the ketamine--butorphanol combination on EA should be further investigated.

Conclusion
==========

Our data provide evidence that injection of ketamine combined with butorphanol before anesthesia induction was more effective than injection of ketamine or butorphanol separately in the prevention of EA. Future studies with a larger number of patients should be performed to validate the findings of our study, which had a small sample size.
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###### 

Characteristics of the study populations

  Characteristics                  Group C (n=50)   Group K (n=50)   Group B (n=50)
  -------------------------------- ---------------- ---------------- ----------------
  Age (years)                      57.3±9.5         58.2±8.6         58.8±9.1
  Male/female                      29/21            30/20            26/24
  Stages according to the ASA                                        
   Stage I                         21               18               17
   Stage II                        17               19               18
   Stage III                       12               13               15
  BMI (kg/m^2^)                    26.1±2.0         25.8±2.2         26.4±2.5
  Operation time (min)             254.7±58.3       268.5±47.9       260.3±66.2
  Intraoperative blood loss (mL)   272.3±98.4       297.4±87.2       291.1±76.5

**Note:** Data are mean ± SD.

**Abbreviations:** ASA, American Society of Anesthesiologists; BMI, body mass index; SD, standard deviation.

###### 

Comparison of MAP and HR among groups at different times

  Groups           n    T0         T1          T2                                                    T3
  ---------------- ---- ---------- ----------- ----------------------------------------------------- -----------------------------------------------------
  MAP (mmHg)                                                                                         
   Group C         50   11.2±1.8   15.8±3.2    12.5±1.7                                              11.4±1.6
   Group K         50   11.4±2.1   15.5±3.7    15.4±2.5[a](#tfn4-tcrm-12-713){ref-type="table-fn"}   13.9±1.4[a](#tfn4-tcrm-12-713){ref-type="table-fn"}
   Group B         50   11.4±2.5   15.6±4.0    15.3±2.2[a](#tfn4-tcrm-12-713){ref-type="table-fn"}   13.5±1.2[a](#tfn4-tcrm-12-713){ref-type="table-fn"}
  HR (beats/min)                                                                                     
   Group C         50   84.7±4.6   104.5±5.8   90.2±3.8                                              84.3±3.3
   Group K         50   85.1±3.8   100.7±6.1   97.4±3.6[a](#tfn4-tcrm-12-713){ref-type="table-fn"}   90.4±3.8[a](#tfn4-tcrm-12-713){ref-type="table-fn"}
   Group B         50   84.5±4.2   101.3±4.9   95.8±4.5[a](#tfn4-tcrm-12-713){ref-type="table-fn"}   91.8±4.0[a](#tfn4-tcrm-12-713){ref-type="table-fn"}

**Notes:** Data are mean ± SD.

Means significant comparing with group C (*P*\<0.05). T0, T1, T2, and T3 represent the HR at the end of operation just before extubation, at 0 minute, at 5 minutes, and at 30 minutes after extubation, respectively.

**Abbreviations:** MAP, mean arterial pressure; HR, heart rate; SD, standard deviation.

###### 

Comparison of the quality of anesthesia recovery among groups

  Groups    n    Recovery time (mins)                                  Extubation time (mins)                                Time in PACU (mins)
  --------- ---- ----------------------------------------------------- ----------------------------------------------------- -----------------------------------------------------
  Group C   50   8.9±3.1                                               9.4±2.5                                               25.7±8.3
  Group K   50   11.5±2.4[a](#tfn7-tcrm-12-713){ref-type="table-fn"}   13.5±3.1[a](#tfn7-tcrm-12-713){ref-type="table-fn"}   34.8±6.4[a](#tfn7-tcrm-12-713){ref-type="table-fn"}
  Group B   50   12.7±2.3[a](#tfn7-tcrm-12-713){ref-type="table-fn"}   13.2±3.2[a](#tfn7-tcrm-12-713){ref-type="table-fn"}   36.5±5.8[a](#tfn7-tcrm-12-713){ref-type="table-fn"}

**Notes:** Data are mean ± SD.

Means significant comparing with group C (*P*\<0.05).

**Abbreviations:** PACU, postanesthesia care unit; SD, standard deviation; mins, minutes.

###### 

Comparison of incidences of EAamong groups

  Groups    n    Stage of EA                                  
  --------- ---- --------------- -------------- ------------- ---
  Group C   50   94.0% (47/50)   6.0% (3/50)    0             0
  Group K   50   76.0% (38/50)   18.0% (9/50)   6.0% (3/50)   0
  Group B   50   80.0% (40/50)   16.0% (8/50)   4.0% (2/50)   0

**Notes:** Data are numbers of agitated patients/total patients. Stage 0: quiet; stage 1: slightly restless to stimuli; stage 2: obviously excited without stimulation; stage 3: delirious and struggling and shouting continuously.

**Abbreviation:** EA, emergence agitation.

###### 

Comparison of the incidence of adverse reactions among groups

  Groups    n    Drowsiness     Glossoptosis   Respiratory depression   Total incidence
  --------- ---- -------------- -------------- ------------------------ -----------------
  Group C   50   4.0% (2/50)    2.0% (1/50)    0                        6.0% (3/50)
  Group K   50   12.0% (6/50)   6.0% (3/50)    4.0% (2/50)              22.0% (11/50)
  Group B   50   2.0% (1/50)    4.0% (2/50)    0                        6.0% (3/50)

**Note:** Data are numbers of agitated patients/total patients.
